Rebecca Manning, MD
Retina Specialist · Raleigh, NCNPI 1457435992
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (57.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. AbbVie accounts for 75.5% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2019 at $6,887 and has fallen 94.3% since, to $395 in 2025.
Across 105 payments — averaging $82.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$7K
- Regeneron Healthcare Solutions, Inc.$665
- Alcon$393
- Genentech USA, Inc.$346
- Novartis$316
- Astellas Pharma US Inc$130
- plus $270 from 7 others
What the payments were for
- Consulting fees$4,98858%
- Speaking & faculty fees$50%
- Travel & lodging$5486%
- Food & beverage$3,10836%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 49 | $6,528 |
| Regeneron Healthcare Solutions, Inc. | 17 | $665 |
| Alcon | 3 | $393 |
| Genentech USA, Inc. | 13 | $346 |
| Novartis | 5 | $316 |
| Astellas Pharma US Inc | 4 | $130 |
| Apellis Pharmaceuticals, Inc. | 6 | $118 |
| Biogen | 2 | $53 |
| Harrow Eye, LLC | 1 | $34 |
| Eyepoint US, Inc. | 2 | $27 |
| Ocular Therapeutix, Inc. | 1 | $18 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $14 |
| Notal Vision, Inc. | 1 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,648 in reported general payments places this provider in the 75th percentile of 34 retina specialist providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 113 | $5,730 |
| ValacyclovirValacyclovir Hcl | 53 | $2,600 |
| Ketorolac Tromethamine | 60 | $2,008 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 76 | $1,404 |
| Latanoprost | 82 | $825 |
| Brimonidine Tartrate | 23 | $748 |
| Dorzolamide Hcl | 16 | $347 |
| Timolol Maleate | 24 | $282 |
| Tobramycin | 12 | $70 |
Paid to pharmacies, not to this prescriber.
Other retina specialist in Raleigh
- Daniel BennettRaleigh$126K
- Raynor CaseyRaleigh$34K
- Sachin MudvariRaleigh$33K
- John ThordsenRaleigh$33K
- John DennyRaleigh$31K
- Laura SnyderRaleigh$5K
- Lekha DesaiRaleigh$3K
- Brian LehpamerRaleigh$3K
- Eugene MilderRaleigh$2K
- Lisa FogelRaleigh$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.